Pappas Matthew A, Herzig Shoshana J, Auerbach Andrew D, Deshpande Abhishek, Blanchard Eunice, Rothberg Michael B
Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.
Center for Value-Based Care Research, Cleveland Clinic, Cleveland, OH, USA.
Antimicrob Steward Healthc Epidemiol. 2025 Feb 12;5(1):e40. doi: 10.1017/ash.2025.10. eCollection 2025.
infection (CDI) is a common and often nosocomial infection associated with increased mortality and morbidity. Antibiotic use is the most important modifiable risk factor, but many patients require empiric antibiotics. We estimated the increased risk of hospital-onset CDI with one daily dose-equivalent (DDE) of various empiric antibiotics compared to management without that daily dose-equivalent.
Using a multicenter retrospective cohort of adults admitted between March 2, 2020 and February 11, 2021 for the treatment of SARS-CoV-2, we used a series of three-level logistic regression models to estimate the probability of receiving each of several antibiotics of interest. For each antibiotic, we then limited our data set to patient-days at intermediate probability of receipt and used augmented inverse-probability weighted models to estimate the average treatment effect of one daily dose-equivalent, compared to management without that daily dose-equivalent, on the probability of hospital-onset CDI.
In 24,406 patient-days at intermediate probability of receipt, parenteral vancomycin increased risk of hospital-onset CDI, with an average treatment effect of 0.0096 cases per daily dose-equivalent (95% CI: 0.0053-0.0138). In 38,003 patient-days at intermediate probability of receipt, cefepime also increased subsequent CDI risk, with an estimated effect of 0.0074 more cases per daily dose-equivalent (95% CI: 0.0022-0.0126).
Among common empiric antibiotics, parenteral vancomycin and cefepime appeared to increase risk of hospital-onset CDI. Causal inference observational study designs can be used to estimate patient-level harms of interventions such as empiric antimicrobials.
艰难梭菌感染(CDI)是一种常见且常为医院获得性感染,与死亡率和发病率增加相关。抗生素使用是最重要的可改变风险因素,但许多患者需要经验性使用抗生素。我们估计了与不使用每日剂量等效(DDE)的各种经验性抗生素相比,使用每日一剂等效抗生素导致医院获得性CDI的风险增加情况。
利用2020年3月2日至2021年2月11日期间因治疗SARS-CoV-2而入院的多中心回顾性成人队列,我们使用一系列三级逻辑回归模型来估计接受几种感兴趣抗生素中每种抗生素的概率。对于每种抗生素,我们随后将数据集限制为接受概率处于中等水平的患者天数,并使用增强逆概率加权模型来估计与不使用每日剂量等效抗生素相比,每日一剂等效抗生素对医院获得性CDI概率的平均治疗效果。
在接受概率处于中等水平的24406个患者天数中,静脉注射万古霉素增加了医院获得性CDI的风险,平均治疗效果为每每日剂量等效0.0096例(95%置信区间:0.0053 - 0.0138)。在接受概率处于中等水平的38003个患者天数中,头孢吡肟也增加了后续CDI风险,估计效果为每每日剂量等效多0.0074例(95%置信区间:0.0022 - 0.0126)。
在常见的经验性抗生素中,静脉注射万古霉素和头孢吡肟似乎增加了医院获得性CDI的风险。因果推断观察性研究设计可用于估计经验性抗菌药物等高风险干预措施对患者的危害。